Shares of Protara Therapeutics, Inc. (NASDAQ:TARA – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the eight brokerages that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation and seven have given a buy recommendation to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $26.25.
A number of equities research analysts have weighed in on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Protara Therapeutics in a research note on Thursday, October 15th. Wall Street Zen upgraded shares of Protara Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, September 5th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Protara Therapeutics in a report on Thursday, October 15th.
View Our Latest Stock Analysis on TARA
Hedge Funds Weigh In On Protara Therapeutics
Several institutional investors have recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP increased its holdings in shares of Protara Therapeutics by 133.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 531,267 shares of the company’s stock valued at $2,767,000 after purchasing an additional 304,110 shares in the last quarter. Bank of New York Mellon Corp acquired a new position in Protara Therapeutics during the second quarter worth about $526,000. Bank of America Corp DE grew its position in Protara Therapeutics by 86.7% during the first quarter. Bank of America Corp DE now owns 925,918 shares of the company’s stock worth $4,824,000 after buying an additional 430,014 shares during the period. Walleye Capital LLC increased its holdings in Protara Therapeutics by 204.0% in the first quarter. Walleye Capital LLC now owns 443,401 shares of the company’s stock valued at $2,310,000 after buying an additional 297,525 shares in the last quarter. Finally, Alps Advisors Inc. increased its holdings in Protara Therapeutics by 36.3% in the third quarter. Alps Advisors Inc. now owns 77,735 shares of the company’s stock valued at $237,000 after buying an additional 20,694 shares in the last quarter. Institutional investors and hedge funds own 38.13% of the company’s stock.
Protara Therapeutics Stock Performance
Shares of Protara Therapeutics stock opened at $2.38 on Thursday. The company has a fifty day simple moving average of $2.86 and a 200-day simple moving average of $4.37. Protara Therapeutics has a 12-month low of $2.09 and a 12-month high of $7.82.
Protara Therapeutics (NASDAQ:TARA – Get Free Report) last issued its quarterly earnings data on Friday, November 6th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.37) by $0.02. Equities research analysts forecast that Protara Therapeutics will post -1.37 earnings per share for the current year.
About Protara Therapeutics
Protara Therapeutics is a clinical-stage biotechnology company developing treatments for cancer and rare diseases. Its programs are investigational and are not approved for general use. The company’s lead program, TARA-002, is a cell-based immunotherapy being studied for non-muscle invasive bladder cancer and lymphatic malformations. Protara is also developing intravenous choline chloride for people with intestinal failure-associated liver disease. Protara was formed in 2019 through a merger involving ArTara Therapeutics.
See Also
- Five stocks we like better than Protara Therapeutics
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Protara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
